Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Robert M. Danovich"'
Autor:
Nathan Vandergrift, Robert M. Danovich, Daria J. Hazuda, Charles B. Hicks, Jia Liu, Fangping Cai, Feng Gao, Michael D. Miller
Publikováno v:
Antimicrobial Agents and Chemotherapy. 55:1114-1119
Raltegravir is highly efficacious in the treatment of HIV-1 infection. The prevalence and impact on virologic outcome of low-frequency resistant mutations among HIV-1-infected patients not previously treated with raltegravir have not been fully estab
Autor:
Charlotte M. Harvey, Joseph J. Eron, Anne R. Meibohm, Kim M. Strohmaier, Robert M. Danovich, Beatriz Grinsztejn, Christine Katlama, Adriano Lazzarin, Robin Isaacs, Daniel Vittecoq, Jing Zhao, Hong Wan, Charles J. Gonzalez, Bach-Yen Nguyen, José M. Gatell
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 53:456-463
Background: Raltegravir in combination therapy has demonstrated potent suppression of HIV-1 with a favorable safety profile. This report provides 96-week efficacy and safety data from Protocol 005, a Phase II study. Methods: HIV-infected patients wit
Autor:
Martin, Markowitz, Bach-Yen, Nguyen, Eduardo, Gotuzzo, Fernando, Mendo, Winai, Ratanasuwan, Colin, Kovacs, Guillermo, Prada, Javier O, Morales-Ramirez, Clyde S, Crumpacker, Robin D, Isaacs, Havilland, Campbell, Kim M, Strohmaier, Hong, Wan, Robert M, Danovich, Hedy, Teppler, K, Tashima
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 52:350-356
The purpose of this study was to evaluate the safety and efficacy of raltegravir vs efavirenz-based antiretroviral therapy after 96 weeks in treatment-naive patients with HIV-1 infection.Multicenter, double-blind, randomized study of raltegravir (100
Autor:
Marc V. Witmer, Robert M. Danovich
Publikováno v:
Methods. 47:277-282
This report describes methods for the selection and analysis of antiretroviral resistance to HIV integrase strand transfer inhibitors (InSTIs) in cell culture. The method involves the serial passage of HIV-1 in the presence of increasing concentratio
Autor:
Donald J. Graham, Malathi Shivaprakash, Kalpana K Bakshi, Rand R. Rhodes, David W. Haas, Jon H. Condra, Joshua Chen, Alfred Saah, Mark J. DiNubile, Daniel J. Holder, Robert M. Danovich
Publikováno v:
The Journal of Infectious Diseases. 187:1157-1162
A prospective, open-label study was conducted to assess the response to indinavir, efavirenz, and adefovir in human immunodeficiency virus (HIV)-infected patients experiencing viral rebound while receiving therapy with nelfinavir-containing regimens,
Autor:
Daria J. Hazuda, Robert M. Danovich, Christos J. Petropoulos, Soumi Gupta, Marc V. Witmer, Michael D. Miller, Signe Fransen, Wei Huang
The human immunodeficiency virus type 1 (HIV-1) integrase mutations N155H and Q148R(H)(K) that reduce susceptibility to the integrase inhibitor raltegravir have been identified in patients failing treatment regimens containing raltegravir. Whether th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c0c19454e88a9f0537871b645aaee9
https://europepmc.org/articles/PMC2772690/
https://europepmc.org/articles/PMC2772690/
Autor:
Daria J. Hazuda, John S. Wai, Lynda Tussey, Neville J. Anthony, Geethanjali Dornadula, Michael D. Miller, John W. Shiver, Joseph P. Vacca, Sherri L. Motzel, Lixia Jin, Robert M. Danovich, Marc V. Witmer, Larry Handt, James P. Guare, Danilo R. Casimiro, Steven D. Young, Lori S. Gabryelski, Hilton J. Klein, Robert P. Gomez, Keith A. Wilson, William A. Schleif, Emilio A. Emini
Publikováno v:
Science (New York, N.Y.). 305(5683)
We describe the efficacy of L-870812, an inhibitor of HIV-1 and SIV integrase, in rhesus macaques infected with the simian-human immunodeficiency virus (SHIV) 89.6P. When initiated before CD4 cell depletion, L-870812 therapy mediated a sustained supp
Autor:
Lori J. Gabryelski, H L Robbins, D Laird, Donald J. Graham, R T Steigbigel, Daniel J. Holder, J A Chodakewitz, Malathi Shivaprakash, O M Blahy, F. E. Massari, Jon H. Condra, Robert M. Danovich, T Yang, Elizabeth Roth, Quintero Julio C, A Rhodes, William A. Schleif, Emilio A. Emini, K E Squires, Deutsch Paul J, Randi Y. Leavitt, J W Mellors, Hedy Teppler
Indinavir (IDV) (also called CRIXIVAN, MK-639, or L-735,524) is a potent and selective inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease. During early clinical trials, in which patients initiated therapy with suboptimal dosages of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b7b97919b851dd2170bcead88bfc7e3
https://europepmc.org/articles/PMC190914/
https://europepmc.org/articles/PMC190914/
Autor:
Niza Frenkel, Eric C. Schirmer, Linda S. Wyatt, Carl H. June, George C. Katsafanas, Robert M. Danovich, Ehud Roffman
A new human herpesvirus has been isolated from CD4+ T cells purified from peripheral blood mononuclear cells of a healthy individual (RK), following incubation of the cells under conditions promoting T-cell activation. The virus could not be recovere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea40cb0b488211051c7601a9adb956c1
https://europepmc.org/articles/PMC53343/
https://europepmc.org/articles/PMC53343/